49 citations
,
December 1997 in “Urology” Tamoxifen effectively treats gynecomastia without causing impotence.
August 2025 in “The Nishinihon Journal of Dermatology” Prednisolone treatment improved symptoms and hair regrowth in a patient with Cronkhite-Canada Syndrome.
215 citations
,
March 2011 in “Clinical Cancer Research” Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
September 2011 in “American Journal of Clinical Dermatology” The birth control pill containing ethinylestradiol and chlormadinone may help treat acne and other skin and hair conditions related to hormones.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
January 2026 in “Food Science and Human Wellness” Krill oil may help reduce prostate enlargement and growth.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
November 2025 in “npj Breast Cancer” Tamoxifen increases the risk of lasting hair loss after chemotherapy despite scalp cooling.
March 2026 in “Journal of obstetrics and gynaecology research” Ark-e-Kasni improves PCOS symptoms and may be a potential treatment.
58 citations
,
July 1974 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Cyproterone acetate combined with ethinyl estradiol significantly reduced hirsutism in women.
November 2022 in “Journal of the Endocrine Society” Removing the ovarian tumor improved the woman's hormonal symptoms.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
May 2025 in “Reactions Weekly” 14 citations
,
June 1982 in “Archives of Dermatology” A man had bad reactions to a hair loss treatment called DNCB.
7 citations
,
September 1988 in “Baillière's clinical obstetrics and gynaecology” Cyproterone acetate is effective for treating hirsutism and acne in women by blocking androgens in the skin and also works as a contraceptive.
1 citations
,
September 2020 in “Actas Dermo-Sifiliográficas” January 2005 in “Urology” Alfuzosin reduces short-term surgery need after catheter removal, but long-term benefits are unclear; combination therapy may help prevent urinary issues.
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.
1 citations
,
December 1989 in “PubMed”
The treatment was ineffective in humans.
1 citations
,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
3 citations
,
June 2024 in “Frontiers in Endocrinology” COC treatment improves hormone and metabolic levels in PCOS patients.
January 2019 in “Przegląd Dermatologiczny” Chemotherapy with docetaxel can cause painful nail and skin side effects that may lead to stopping treatment.
294 citations
,
March 2016 in “European journal of cancer” Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
January 1987 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Norethisterone (jenapharm) therapy is effective for endometrial cancer.
April 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Chronic use of 1 mg/day finasteride for hair loss may delay prostate cancer diagnosis by lowering PSA levels.
16 citations
,
March 2000 in “Clinical Biochemistry” Women with hair loss had higher levels of certain hormones, suggesting a link to a condition like PCOS.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.